Download MendeleyDiscovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent.
Shao, Y.X., Huang, M., Cui, W., Feng, L.J., Wu, Y., Cai, Y., Li, Z., Zhu, X., Liu, P., Wan, Y., Ke, H., Luo, H.B.(2014) J Med Chem 57: 10304-10313
- PubMed: 25432025
- DOI: https://doi.org/10.1021/jm500836h
- Primary Citation of Related Structures:
4QGE - PubMed Abstract:
Phosphodiesterase 9 (PDE9) inhibitors have been studied as potential therapeutics for treatment of diabetes and Alzheimer's disease. Here we report a potent PDE9 inhibitor 3r that has an IC50 of 0.6 nM and >150-fold selectivity over other PDEs. The HepG2 cell-based assay shows that 3r inhibits the mRNA expression of phosphoenolpyruvate carboxykinase and glucose 6-phosphatase. These activities of 3r, together with the reasonable pharmacokinetic properties and no acute toxicity at 1200 mg/kg dosage, suggest its potential as a hypoglycemic agent. The crystal structure of PDE9-3r reveals significantly different conformation and hydrogen bonding pattern of 3r from those of previously published 28s. Both 3r and 28s form a hydrogen bond with Tyr424, a unique PDE9 residue (except for PDE8), but 3r shows an additional hydrogen bond with Ala452. This structure information might be useful for design of PDE9 inhibitors.
Organizational Affiliation:
School of Pharmaceutical Sciences, Sun Yat-Sen University , Guangzhou 510006, P. R. China.
